title: Effects of pharmaceuticals on the expression of genes involved in detoxification in a carp primary hepatocyte model.
abstract: Fish in many surface freshwaters are exposed to a range of pharmaceuticals via wastewater treatment works effluent discharges. In mammals the pregnane X receptor (PXR) plays a key role in the regulation of a suite of genes involved in drug biotransformation, but information on the role of this response pathway in fish is limited. Here we investigated the effects of exposure of carp (Cyprinus carpio) primary hepatocytes to the human PXR agonist rifampicin (RIF) on expression of target genes involved in phase I (cyp2k, cyp3a) and phase II (gstα, gstπ) drug metabolism and drug transporters mdr1 and mrp2. RIF induced expression of all target genes measured and the PXR antagonist ketoconazole (KET) inhibited responses of cyp2k and cyp3a. Exposure of the primary carp hepatocytes to the pharmaceuticals ibuprofen (IBU), clotrimazole (CTZ), clofibric acid (CFA) and propranolol (PRP), found responses to IBU and CFA, but not CTZ or PRP. This is in contrast with mammals, where CTZ is a potent PXR-agonist. Collectively our data indicate potential PXR involvement in regulating selected genes involved in drug metabolism in fish, but suggest some divergence in the regulation pathways with those in mammals. The carp primary hepatocyte model serves as a useful system for screening for responses in these target genes involved in drug metabolism.
authors.affiliation: University of Exeter, Biosciences, College of Life & Environmental Sciences, Exeter, United Kingdom.
authors.forename: Jenna
authors.initials: J
authors.lastname: Corcoran
authors.forename: Anke
authors.initials: A
authors.lastname: Lange
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Winter
authors.forename: Charles R
authors.initials: CR
authors.lastname: Tyler
mesh_terms: D000818:Animals; D002347:Carps / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D051544:Cytochrome P-450 CYP3A / Q000096:biosynthesis / Q000235:genetics; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics*; D008297:Male; D008954:Models, Biological; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D012293:Rifampin / Q000494:pharmacology; D017422:Sequence Analysis, DNA; D013997:Time Factors
chemical_list: D004364:Pharmaceutical Preparations; D051544:Cytochrome P-450 CYP3A; D012293:Rifampin